Terence Ching, PhD
InstructorCards
About
Titles
Instructor
Biography
Terence Ching (he/him) is a licensed clinical psychologist and instructor in the Department of Psychiatry. Terence co-leads psilocybin clinical trials for OCD and other disorders as part of the Yale OCD Research Clinic, Emerging and Novel Applications for Consciousness-Altering Therapeutics (ENACT) Lab, and the Yale Program for Psychedelic Science.
Terence received his PhD in clinical psychology from the University of Connecticut. Prior to moving to the United States, Terence received his Bachelor’s and Master’s degrees in psychology from the National University of Singapore.
He has interests and expertise in: (1) fear-/trauma-based disorders (OCD, anxiety disorders, PTSD); (2) exposure-based, integrative cognitive-behavior therapies (CBT); (3) culturally attuned care; and (4) therapeutic applications of psychedelics.
Terence has completed clinical training in a variety of settings, including the University of Connecticut, the Institute of Living, as well as Dartmouth-Hitchcock Medical Center. Terence approaches psychotherapy from an evidence-based and culturally attuned perspective, and specializes in exposure-based CBT for fear-/trauma-based disorders. Terence has also received training in functional analytic psychotherapy (FAP).
Additionally, Terence is a MAPS-certified psychedelic therapist in MDMA-assisted therapy (MDMA-AT) for PTSD. Further, Terence has experience providing ketamine-assisted psychotherapy (KAP) for individuals with depressive and anxiety disorders, and PTSD.
Appointments
Education & Training
- Psychology Intern
- Dartmouth-Hitchcock Medical Center (2021)
- PhD
- University of Connecticut, Clinical Psychology (2021)
Research
Publications
Featured Publications
Causal attributions and OCD treatment response: A linguistic analysis of OCD patients' self-reported etiological explanations in intensive residential treatment.
Ching THW, Pinciotti CM, Farrell NR. Causal attributions and OCD treatment response: A linguistic analysis of OCD patients' self-reported etiological explanations in intensive residential treatment. Scand J Psychol 2022 PMID: 36580071, DOI: 10.1111/sjop.12896.Peer-Reviewed Original ResearchMDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial.
Ching TH, Williams MT, Wang JB, Jerome L, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial. Journal Of Psychopharmacology (Oxford, England) 2022, 2698811221104052. PMID: 35727042, DOI: 10.1177/02698811221104052.Peer-Reviewed Original ResearchSafety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial
Ching T, Grazioplene R, Bohner C, Kichuk S, DePalmer G, D’Amico E, Eilbott J, Jankovsky A, Burke M, Hokanson J, Martins B, Witherow C, Patel P, Amoroso L, Schaer H, Pittenger C, Kelmendi B. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Frontiers In Psychiatry 2023, 14: 1178529. PMID: 37181888, PMCID: PMC10166878, DOI: 10.3389/fpsyt.2023.1178529.Peer-Reviewed Original ResearchObsessive-compulsive disorderPrimary endpointPsilocybin effectsNeural effectsRefractory obsessive-compulsive disorderNon-crossover designOpen-label doseStandard care treatmentOpen-label studyVisual analog scale ratingsTreatment of OCDEffects of psilocybinOCD symptomsInstitutional review boardYale-Brown ObsessivePrimary outcomeSingle doseCare treatmentOral psilocybinInformed consentReview boardNeurobiological mechanismsCompulsive ScalePsychological supportTrials
2024
Sexual orientation-themed obsessive-compulsive disorder in a lesbian woman: Phenomenology and implications for affirmative assessment and treatment
Schild S, Moore A, Mattera E, Fitzpatrick M, Entezar T, Fram G, Ching T. Sexual orientation-themed obsessive-compulsive disorder in a lesbian woman: Phenomenology and implications for affirmative assessment and treatment. Psychiatry Research Case Reports 2024, 3: 100211. DOI: 10.1016/j.psycr.2024.100211.Peer-Reviewed Original ResearchSexual identitySexual orientation questionsObsessive-compulsive disorderInternalized homophobiaLesbian womenLGBTQ+ individualsAffirming careSexual orientationHeterosexual samplesCisgender womenAffirmative mannerLGBTQ+Orientation questionsHeterosexual patientsIntrusive doubtsCase exampleIdentityHomophobiaTransgenderWomenDanielleSexualityTherapy proceduresDisordersCommunitySuicidal Obsessions or Suicidal Ideation? A Case Report and Practical Guide for Differential Assessment
Mattera E, Ching T, Zaboski B, Kichuk S. Suicidal Obsessions or Suicidal Ideation? A Case Report and Practical Guide for Differential Assessment. Cognitive And Behavioral Practice 2024, 31: 259-271. DOI: 10.1016/j.cbpra.2022.09.002.Peer-Reviewed Original ResearchSuicidal ideationCognitive-behavioral frameworkBehavioral criteriaLow familiarityBehavioral frameworkBehavioral responsesFuture researchCommon measurement toolsExtant literatureOCDCase exampleEvidence-based guideDifferential assessmentObsessionIdeationThoughtMeasurement toolsEmotionsPractical guideFamiliaritySuicidalityInaccurate assessmentInterventionClientsPhenomenologyMechanisms of therapeutic change after psychedelic treatment in OCD
Maloney G, Ching T, Kichuk S, Pittenger C, Kelmendi B. Mechanisms of therapeutic change after psychedelic treatment in OCD. Psychiatry Research 2024, 336: 115907. PMID: 38615521, PMCID: PMC11190873, DOI: 10.1016/j.psychres.2024.115907.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderMechanisms of therapeutic changeAversive eventsImagery rescriptingPsychedelic treatmentPsychotherapeutic treatmentPsychotherapeutic frameworkSymptom reductionTherapeutic changePsychotherapyNegative emotionsPsychological mechanismsCore beliefsPilot dataNovel treatmentRescriptingEmotionsDisordersSymptomsReprocessingTreatmentBeliefsResistance to first-lineIndividualsInterventionEffects of Sexual and Gender Minority Stress on Depressive Symptoms Among Adolescents of Color in the United States
Ching THW, Finkelstein-Fox L, Lee SY, Watson RJ. Effects of Sexual and Gender Minority Stress on Depressive Symptoms Among Adolescents of Color in the United States. Cultural Diversity & Ethnic Minority Psychology 2024, 30: 309-318. PMID: 36048116, PMCID: PMC9975117, DOI: 10.1037/cdp0000562.Peer-Reviewed Original ResearchAssociations between gendered racism, racial identity, and nicotine use among Asian American men
Le T, Iwamoto D, Ching T. Associations between gendered racism, racial identity, and nicotine use among Asian American men. Journal Of Clinical Psychology 2024, 80: 1582-1595. PMID: 38509784, DOI: 10.1002/jclp.23681.Peer-Reviewed Original ResearchConceptsNicotine useAsian American menGendered racismRacial identity statusesAssociated with greater conformityAmerican menUnited States of AmericaIdentity statusIntervention targetsIntersectional frameworkNicotineRacial identityRacist beliefsRacismStates of AmericaUnited StatesPrimary analysisCross-sectional surveyEmasculationEndorsementMenCorrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 15: 1372373. PMID: 38435972, PMCID: PMC10905264, DOI: 10.3389/fpsyt.2024.1372373.Peer-Reviewed Original ResearchCapturing Synergy Holistically in Psychedelic Clinical Trials: Assessing Processes in Addition to Outcomes.
Ching THW, Shnayder S. Capturing Synergy Holistically in Psychedelic Clinical Trials: Assessing Processes in Addition to Outcomes. Clin Pharmacol Ther 2024 PMID: 38168006, DOI: 10.1002/cpt.3129.Commentaries, Editorials and Letters
Clinical Trials
Current Trials
Effects of Repeated Psilocybin Dosing in OCD
HIC ID2000032623RoleSub InvestigatorPrimary Completion Date04/30/2026Recruiting ParticipantsGenderBothAge18 years - 65 yearsObsessions or ideations: First Person Suicide Images study in OCD
HIC ID2000033121RoleSub InvestigatorPrimary Completion Date08/31/2024Recruiting ParticipantsBrain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
HIC ID2000023688RoleSub InvestigatorPrimary Completion Date07/31/2024Recruiting ParticipantsGenderBothAge18 years - 65 yearsEfficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.
HIC ID2000020355RoleSub InvestigatorPrimary Completion Date07/31/2023Recruiting ParticipantsGenderBothAge21 years - 55 years